EGFR tyrosine kinase inhibitors in squamous cell lung cancer
Mené sur 795 patients atteints d'un carcinome épidermoïde du poumon de stade avancé, cet essai international de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'afatinib et de l'erlotinib pour un traitement de deuxième ligne
Compared with lung adenocarcinoma, for which recent therapeutic strategies directed against driver oncogenes such as EGFR mutation and ALK translocations have led to new treatment options, progress in the management of advanced squamous cell carcinoma of the lung has been modest at best.
The Lancet Oncology , commentaire, 2014